XIPERE® (triamcinolone acetonide)

About Clearside Biomedical

Clearside Biomedical is revolutionizing ocular therapeutics through its proprietary suprachoroidal space (SCS) delivery platform. The company's mission is to preserve and improve vision by enabling targeted, in-office administration of therapies directly to the choroid, retina, and macula. Its strategy is validated by the commercial approval of XIPERE® and is centered on advancing its lead internal asset, CLS-AX for wet AMD, into Phase 3, while leveraging its platform through strategic collaborations with other biopharma companies to expand the pipeline across multiple retinal indications.

Therapeutic Areas